SMURF2 and non-small cell lung carcinoma: Indeed, we have demonstrated that suppression of SMURF2 expression is tightly involved in the regulation of osimertinib-induced Topo IIα degradation because enforced overexpression of the ectopic SMURF2 gene in EGFRm NSCLC cells elevated basal levels of Topo IIα and attenuated the ability of osimertinib to decrease Topo IIα levels, while knockdown of SMURF2 expression resulted in facilitation of Topo IIα degradation and substantial reduction of Topo IIα levels in these cell lines.